Keywords: Geron Corp, GRN1005, Discontinuation, Imetelstat, Brain cancer, hematological malignancies, Restructuring

Geron discontinues GRN1005 to concentrate on imetelstat; will cut jobs

Article | 05 December 2012

Print This

California, USA-based Geron Corp (Nasdaq: GERN), which scrapped its stem cell business a year ago to focuses on cancer treatments, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in